These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10846597)

  • 21. HIV resistance testing proves its value.
    Proj Inf Perspect; 1999 Sep; (28):14. PubMed ID: 11367356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes.
    Holguín A; Ramirez de Arellano E; Rivas P; Soriano V
    AIDS Rev; 2006; 8(2):98-107. PubMed ID: 16848277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
    Wainberg MA; Sawyer JP; Montaner JS; Murphy RL; Kuritzkes DR; Raffi F
    Antivir Ther; 2005; 10(1):13-28. PubMed ID: 15751760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance tests: what do clinical trials tell us?
    Price N; Smit E; Pillay D
    J HIV Ther; 2002 Nov; 7(4):80-6. PubMed ID: 12733605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of resistance testing in the management of HIV-1-infected patients.
    Grant PM; Zolopa AR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):474-80. PubMed ID: 20048713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding transmitted HIV resistance through the experience in the USA.
    Taiwo B
    Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interpretation of resistance assay results.
    Miller V
    Antivir Ther; 2001; 6 Suppl 2():1-9. PubMed ID: 11678473
    [No Abstract]   [Full Text] [Related]  

  • 28. Opinion paper. Resistance to new anti-HIV agents: problems in the pathway of drug registration.
    Dalmau D; Klimkait T; Telenti A
    Antivir Ther; 2005; 10(7):867-72. PubMed ID: 16312184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral resistance.
    Geretti AM
    J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
    [No Abstract]   [Full Text] [Related]  

  • 30. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.
    Zaccarelli M; Perno CF; Forbici F; Cingolani A; Liuzzi G; Bertoli A; Trotta MP; Bellocchi MC; Di Giambenedetto S; Tozzi V; Gori C; D'Arrigo R; De Longis P; Noto P; Girardi E; De Luca A; Antinori A
    Antivir Ther; 2003 Feb; 8(1):51-6. PubMed ID: 12713064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance against reverse transcriptase inhibitors.
    O'Brien WA
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S185-92. PubMed ID: 10860904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James.
    Feigal D
    AIDS Treat News; 1997 Jun; (No 273):1-5. PubMed ID: 11364399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study on mutations and antiretroviral therapy (SMART): preliminary results.
    Gianotti N; Moretti F; Tambussi G; Racca S; Presi S; Crucianelli R; Carrera P; Ferrari M; Lazzarin A
    Antivir Ther; 1999; 4 Suppl 3():65-9. PubMed ID: 16021873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotypic drug resistance interpretation systems--the cutting edge of antiretroviral therapy.
    Schmidt B; Walter H; Zeitler N; Korn K
    AIDS Rev; 2002; 4(3):148-56. PubMed ID: 12416449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 antiretroviral resistance testing laboratories.
    Hofherr LK; Francis DP; Astles JR; Schalla WO
    Clin Lab Sci; 2002; 15(4):213-9. PubMed ID: 12776781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral therapy. Sequencing antiretrovirals.
    MacArthur RD
    AIDS Read; 2000 Jun; 10(6):359-64. PubMed ID: 10881367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel.
    Hirsch MS; Brun-Vézinet F; Clotet B; Conway B; Kuritzkes DR; D'Aquila RT; Demeter LM; Hammer SM; Johnson VA; Loveday C; Mellors JW; Richman DD;
    Top HIV Med; 2003; 11(4):150-4. PubMed ID: 12876334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection.
    Call SA; Saag MS; Westfall AO; Raper JL; Pham SV; Tolson JM; Hellmann NS; Cloud GA; Johnson VA
    J Infect Dis; 2001 Feb; 183(3):401-8. PubMed ID: 11133371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond.
    Murphy RL
    AIDS Clin Care; 1999 Jun; 11(6):47-9, 51, 53-4. PubMed ID: 11366882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incorporating drug-resistance measurements into the clinical management of HIV-1 infection.
    Zolopa AR
    J Infect Dis; 2006 Sep; 194 Suppl 1():S59-64. PubMed ID: 16921474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.